Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC upgrades Berkeley and Persimmon in housebuilder ratings reshuffle

(Sharecast News) - RBC Capital Markets has reshuffled its ratings across the UK housing sector amid a "two-speed housing market", raising its recommendations for Berkeley and Persimmon, and cutting its stances on Bellway and Taylor Wimpey. RBC said that recent data has been "healthy": mortgage approvals back at pre-Covid levels; housing transactions are returning to normal following a lull after the stamp duty change that came into effect in April; house prices are stable; while mortgage rates are trending downwards.

But the new planning rules announced by the Labour government still need to be enforced, and the social and affordable housing finance still needs to be released. Until local authorities start putting these new measures into place, site openings will not accelerate, the broker said.

"Recent housing market datapoints and key leading indicators paint a picture of health for the UK housing market as a whole, but the new build sector is still being hamstrung by planning and social housing funding delays. If they can't build them, they can't sell them," RBC said in a research note on Wednesday.

"Current sector valuations suggest that investors are concerned about volume downgrades and recovery being pushed to the right."

As a result, some housebuilders are faring better than others, and so the broker has adjusted its ratings across the sector to reflect this.

RBC has raised Berkeley from 'underperform' to 'outperform', and lifted Persimmon from 'underperform' to 'sector perform', while lowering Bellway and Taylor Wimpey from 'outperform' to 'sector perform'.

Meanwhile, Barratt Redrow and Crest Nicholson have been left at 'outperform', while ratings for Gleeson and Vistry stay at 'underperform'.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.